Flu urges vaccine rush
Peter Robins
Thomson Scientific
January 2006
The threat of avian flu is fuelling an already growing interest in the vaccines market. This article, originally published in Pharmaceutical Marketing Europe (Winter 2005), includes a look at the obstacles for vaccine manufacturers, and at the response to avian flu by large pharmaceutical companies.
Vaccines have received much press interest in the past few years due to discussion of severe acute respiratory syndrome (SARS), bioterrorism, the combined MMR vaccine, and — more recently — avian flu (H5N1). However vaccines currently represent less than 3% of the overall global drug market.
Download this article to find out more about the rising interest in vaccines from large pharmaceutical companies
Additional information
Flu urges vaccine rush:
download the full article here(1MB PDF)
Thomson Pharma can keep you up to date with vaccine developments at all stages of the drug development pipeline